← Back to Clinical Trials
Recruiting NCT06032780

NCT06032780 Eccentric Resistance Training Among Individuals With Chronic Heart Failure

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06032780
Status Recruiting
Phase
Sponsor Riphah International University
Condition Heart Failure
Study Type INTERVENTIONAL
Enrollment 84 participants
Start Date 2023-09-20
Primary Completion 2026-05

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Eccentric Resistive Training + Aerobic training GroupResistance Training + Aerobic training GroupAerobic training Group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 84 participants in total. It began in 2023-09-20 with a primary completion date of 2026-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To determine the effects of eccentric resistive training on ventricle functions and aerobic capacity as compared to a resistance and aerobic training among Heart failure (HF)

Eligibility Criteria

Inclusion Criteria: * Diagnosis of Chronic HF and currently stable with optimal medical therapy * Chronic Heart failure with ejection fraction \> 30 % * Patient able to safely perform lower limb exercise will be check by six- minute walk test (6 MWT) Exclusion Criteria: * Those Heart failure patient whose are in acute phase or planed for any immediate medical intervention * Already participating in cardiac rehabilitation * New York Heart Association (NYHA) Classification of HF class IV HF symptoms * Co-existent other disease such as asthma/ COPD/interstitial lung disease. * Symptomatic Second degree or third degree heart block. * ECG with uncontrolled ventricular arrhythmia * Limited Exercise ability due to neurologic or orthopedic impairments of the legs (will cross-check with 6 MWT)

Contact & Investigator

Central Contact

Muhammad Iqbal Tariq, PhD*

✉ iqbal.tariq@riphah.edu.pk

📞 +923338236752

Principal Investigator

Muhammad Iqbal Tariq, PhD*

PRINCIPAL INVESTIGATOR

Riphah International University

Frequently Asked Questions

Who can join the NCT06032780 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06032780 currently recruiting?

Yes, NCT06032780 is actively recruiting participants. Contact the research team at iqbal.tariq@riphah.edu.pk for enrollment information.

Where is the NCT06032780 trial being conducted?

This trial is being conducted at Rawalpindi, Pakistan, Rawalpindi, Pakistan.

Who is sponsoring the NCT06032780 clinical trial?

NCT06032780 is sponsored by Riphah International University. The principal investigator is Muhammad Iqbal Tariq, PhD* at Riphah International University. The trial plans to enroll 84 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology